Jounce Therapeutics Inc

NASDAQ:JNCE   3:59:57 PM EDT
7.12
-0.15 (-2.06%)
Products

Jounce Therapeutics Receives Study May Proceed Letter From US FDA To Initiate Phase 1 Clinical Trial Of JTX-8064 Targeting LILRB2/ILT4 Mechanism

Published: 11/16/2020 13:49 GMT
Jounce Therapeutics Inc (JNCE) - Jounce Therapeutics Receives Study May Proceed Letter From US FDA to Initiate Phase 1 Clinical Trial of Jtx-8064 Targeting the Lilrb2/ilt4 Mechanism.
Jounce Therapeutics Inc - Phase 1 Innate Trial Will Evaluate Jtx-8064 As a Monotherapy and in Combination With Jounce's Pd-1 Inhibitor, Jtx-4014.
Jounce Therapeutics Inc - on Track to Begin Enrollment by Year-end 2020.